TAILOR: A phase III trial comparing erlotinib with docetaxel as the second-line treatment of NSCLC patients with wild-type (wt) EGFR.
暂无分享，去创建一个
R. Labianca | I. Floriani | S. Marsoni | M. Broggini | S. Veronese | F. Longo | C. Lauricella | G. Gherardi | A. Bettini | A. Scanni | M. Tomirotti | M. Fabbri | M. Ganzinelli | O. Alabiso | G. Farina | O. Martelli | M. Marabese | E. Copreni | M. Sarobba